FRE — Firebrick Pharma Share Price
Last trade - 00:00- AU$14.71m
- AU$13.80m
- AU$0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.83 | ||
| Price to Tang. Book | 9.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 69.62 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -176.61% | ||
| Return on Equity | -111.71% | ||
| Operating Margin | -1251.39% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | n/a | n/a | 0 | 0 | 0.01 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Firebrick Pharma Limited is an Australia-based pharmaceutical company. The principal activity for the Company is the clinical development and partnering of Nasodine, a broad-spectrum antimicrobial spray for the treatment of the common cold. The Company has developed a povidone-iodine nasal spray, called Nasodine Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the United States, Europe and Australia. The Company has also completed six clinical trials for Nasodine, including a Phase I study, three Phase II studies and two Phase III studies, which have affirmed the product’s safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings. Nasodine Phase II COVID-19 trail achieves primarily endpoints.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 12th, 2012
- Public Since
- January 28th, 2022
- No. of Shareholders
- 4,125
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 210,108,508
- Address
- Level 10, 440 Collins Street, MELBOURNE, 3000
- Web
- https://firebrickpharma.com/
- Phone
- +61 300301874
- Auditors
- BDO Audit (WA) PTY LTD
Upcoming Events for FRE
Similar to FRE
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
As of Today at 20:38 UTC, shares in Firebrick Pharma are trading at AU$0.07. This share price information is delayed by 15 minutes.
Shares in Firebrick Pharma last closed at AU$0.07 and the price had moved by +12.9% over the past 365 days. In terms of relative price strength the Firebrick Pharma share price has outperformed the ASX All Ordinaries Index by +8.81% over the past year.
There is no consensus recommendation for this security.
Find out moreFirebrick Pharma does not currently pay a dividend.
Firebrick Pharma does not currently pay a dividend.
Firebrick Pharma does not currently pay a dividend.
To buy shares in Firebrick Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.07, shares in Firebrick Pharma had a market capitalisation of AU$14.71m.
Here are the trading details for Firebrick Pharma:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: FRE
Based on an overall assessment of its quality, value and momentum Firebrick Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Firebrick Pharma. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +26.33%.
As of the last closing price of AU$0.07, shares in Firebrick Pharma were trading +7.99% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Firebrick Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Firebrick Pharma's directors